Chemical Structure : SR-16157
CAS No.:
943344-76-1
SR-16157
(NSC 732011;SR16157;HLX 801)
Catalog No.: PC-61433Not For Human Use, Lab Use Only.
A novel dual-acting steroid sulfatase inhibitor (IC50=0.1 uM) and selective ERα modulator (SERM).
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Purity & Documentation Purity:
>98% (HPLC)
Biological Activity
A novel dual-acting steroid sulfatase inhibitor (IC50=0.1 uM) and selective ERα modulator (SERM); exerts STS inhibition and antiestrogenic effects, 10 times more potent than the antiestrogens SR-16137 and tamoxifen in cell growth and ERα function test in MCF-7 breast cancer cells; displays profoundly improved ERα binding affinity and antiestrogenic effects on expression of estrogen-regulated genes.
Breast Cancer
Phase 2 Clinical
Physicochemical Properties
|
M.Wt
|
492.719
|
|
Formula
|
C27H44N2O4S
|
|
Appearance
|
Solid
|
|
CAS No.
|
|
|
Storage
|
- Solide Powder
-
-20 °C 12 Months; 4°C 6 Months
|
- In Solvent
-
-80 °C 6 Months; -20°C 6 Months
|
|
Shipping
|
|
|
Solubility
|
10 mM in DMSO
|
|
Chemical Name/SMILES
|
(7R,17R)-17-(2-(2-(diethylamino)ethoxy)ethyl)-7,13-dimethyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl sulfamate
|
References
1. Rasmussen LM, et al. Breast Cancer Res Treat. 2007 Dec;106(2):191-203.
2. Rausch L, et al. Cancer Chemother Pharmacol. 2011 Jun;67(6):1341-52.
3. Wang J, et al. J Pharm Biomed Anal. 2007 Nov 30;45(4):572-82.
Contact Us
sales@probechem.com
